Alvotech
ALVO · XNASCIK 1898416fmd_0ZFXBT262XYPXZ8FDCC1GNC97FManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Dec 31, 2025, 10 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 67 | 37 | 83 | 91 | 490 | 586 |
| Cost of revenue | – | 0 | 64 | 161 | 185 | 236 |
| Gross profit | – | 37 | 19 | (69) | 304 | 351 |
| Research and development | 148 | 191 | 181 | 211 | 171 | 184 |
| Operating income | (138) | (235) | (346) | (355) | 70 | 78 |
| Interest expense | 162 | 117 | 188 | 267 | 303 | 149 |
| Income before taxes | (292) | (149) | (552) | (651) | (218) | 136 |
| Income tax expense | (122) | (48) | (38) | (99) | 14 | 108 |
| Net income from continuing operations | (170) | (102) | (514) | (552) | (232) | 28 |
| Net income | (170) | (102) | (514) | (552) | (232) | 28 |